Abstracts tagged "Intervention"

Abstract Number: 1053 • ACR Convergence 2024
Pilot Intervention to Improve Medication Adherence Among Patients with Rheumatic Diseases
Kai Sun¹, Lisa Carnago², Isaac Smith³, Brian Andonian¹, Stephen Balevic¹, Ankoor Shah¹, Catherine Sims⁴, Kathryn Pollak⁵, Amy Corneli⁵, Hayde Bosworth⁵ and Megan Clowse⁶, ¹Duke University, Durham, NC, ²Duke Health, Hillsborough, NC, ³Duke University Hospital, Durham, NC, ⁴Duke University, Knightdale, NC, ⁵Duke University, Durham, ⁶Duke University, Chapel Hill, NC
Background/Purpose: Medication nonadherence is as high as 75% among patients with rheumatic diseases, leading to increased morbidity, mortality, and cost. Existing adherence interventions tend to…
Abstract Number: 1058 • ACR Convergence 2024
Bridging the Care Gap Between Hospital Discharge and Outpatient Care Transition for Pediatric Rheumatology Patients: An RN-led Quality Improvement Project
Adrienne Ramirez¹, Lisa Walker-Vischer² and Tzielan Lee³, ¹Stanford Medicine - Children's Health, Palo Alto, CA, ²San Jose State University, Campbell, CA, ³Stanford University School of Medicine, Palo Alto, CA

Background/Purpose: When pediatric rheumatology patients are discharged from a hospital, the period between hospital discharge & outpatient care transition creates a care gap when there…
Abstract Number: 1509 • ACR Convergence 2023
Calcineurin Inhibitors for Treatment of Lupus Nephritis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Gabriel Figueroa-Parra¹, Maria Cuellar-Gutierrez¹, Mariana Gonzalez-Trevino¹, Larry J. Prokop², M. Hassan Murad³ and Ali Duarte-Garcia⁴, ¹Division of Rheumatology, Mayo Clinic, Rochester, MN, ²Mayo Clinic Libraries, Mayo Clinic, Rochester, MN, ³Evidence-based Practice Center, Mayo Clinic, Rochester, MN, ⁴Mayo Clinic, Rochester, MN
Background/Purpose: The current recommendations for the treatment of LN consider as the standard of care (SoC) the use of MMF or CYC. Considering the expanding…
Abstract Number: 1583 • ACR Convergence 2023
Comparison of Two Dosing Schedules for Oral Methotrexate (Split-Dose versus Single-Dose) Once Weekly in Patients with Active Rheumatoid Arthritis: A Multicenter, Open Label, Parallel Group, Randomized Controlled Trial (SMART Study)
Chandra Bhushan Prasad¹, Varun Dhir², Ranjan Gupta³, Koshy Nithin Thomas⁴, Devarasetti phani kumar⁵, VENKATESH S PAI⁶, Avinash Jain⁷, Shankar Naidu⁸, Priya Saini⁸, Leishangthem Bidyalaxmi⁸, AASTHA KHULLAR⁸, Ramesh Manthri⁹, Shefali Sharma¹⁰, Aman Sharma¹¹, Amita Aggarwal⁴ and Sanjay Jain⁸, ¹Healthway Hospital, Goa, Zuarinagar, India, ²PGIMER, CHD, INDIA, Chandigarh, India, ³All India Institute of Medical Sciences, New Delhi, India, ⁴Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India, ⁵Nizams Institute of Medical Sciences, Hyderabad, India, ⁶AIIMS RISHIKESH, Rishikesh, India, ⁷SMS Medical College, Lucknow, India, ⁸PGIMER, Chandigarh, India, ⁹Department of Clinical Immunology and Rheumatology, Nizams Institute of Medical Sciences, Hyderabad, India, ¹⁰PGIMER< Chandigarh, Chandigarh, India, ¹¹PGIMER, Chandigarh, India, Chandigarh, India
Background/Purpose: Methotrexate (MTX), the anchor drug for rheumatoid arthritis (RA), has limited bioavailability above an oral dose of 15 mg. Split-dose oral MTX (morning, evening…
Abstract Number: 1610 • ACR Convergence 2023
Digital Acceptance and Commitment Therapy Improves Fibromyalgia Outcomes: Results from a Pivotal, Multi-center, Randomized Controlled Trial
Michael Gendreau¹, Andrea Chadwick², Lance McCracken³, David Williams⁴, Daniel Clauw⁵, Juan Luciano⁶, Yifei Dai⁷, Nicolette Vega⁸, Zunera Ghalib⁸, Kristen Guthrie⁸, Allison Kraus⁸, Michael Rosenbluth⁸, Jennifer Zomnir⁹, Dana Reddy¹⁰ and Lesley arnold¹¹, ¹Gendreau Consulting, LLC, Poway, CA, ²Department of Anesthesiology, Pain, and Perioperative Medicine, University of Kansas School of Medicine, Kansas City, KS, ³Department of Psychology, Uppsala University, Uppsala, Sweden, ⁴Chronic Pain and Fatigue Research Center, Department of Anesthesiology, University of Michigan, Ann Arbor, MI, ⁵Department of Anesthesiology, University of Michigan, Ann Arbor, MI, ⁶Department of Clinical and Health Psychology, Universitat Autónoma de Barcelona, Barcelona, Spain, ⁷Swing Therapeutics, Gainesville, FL, ⁸Swing Therapeutics, San Francisco, CA, ⁹DelRicht Resesarch, Mckinney, TX, ¹⁰Curavit, Scarsdale, NY, ¹¹Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati, Cincinnati, OH
Background/Purpose: Acceptance and Commitment Therapy (ACT), a form of guideline-recommended Cognitive Behavioral Therapy (CBT), has been empirically validated as a non-drug treatment for fibromyalgia (FM).…
Abstract Number: 1618 • ACR Convergence 2023
Intervention to Improve Medication Adherence Among Patients with SLE
Kai Sun¹, Nneka Molokwu¹, Emily Hanlen¹, Amy Corneli², Kathryn Pollak¹, Jennifer Rogers¹, Rebecca Sadun¹, Lisa Criscione-Schreiber², Jayanth Doss¹, Hayden Bosworth¹ and Megan Clowse³, ¹Duke University, Durham, NC, ²Duke University School of Medicine, Durham, NC, ³Duke University, Chapel Hill, NC
Background/Purpose: Medication nonadherence is common and is associated with increased disease activity, morbidity, and mortality in SLE. To optimize medication adherence and SLE outcomes, we…
Abstract Number: 1861 • ACR Convergence 2023
Efficacy of Non-pharmacological Interventions: A Systematic Review Informing the 2023 EULAR Recommendations for the Management of Fatigue in People with Inflammatory Rheumatic and Musculoskeletal Diseases
Eduardo Santos¹, Bayram Farisogullari², Emma Dures³, Rinie Geenen⁴ and Pedro Machado⁵, ¹Health Sciences Research Unit: Nursing (UICISA: E), Nursing School of Coimbra (ESEnfC), Coimbra, Portugal, ²Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey, ³Academic Rheumatology, Bristol Royal Infirmary; and Faculty of Health and Applied Sciences, University of the West of England, Bristol, United Kingdom, ⁴Utrecht University, Vorstenbosch, Netherlands, ⁵Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, UK. Department of Rheumatology, Northwick Park Hospital, London North West University Healthcare NHS trust, London, UK., London, United Kingdom
Background/Purpose: To identify the best evidence on the efficacy of non-pharmacological interventions in reducing fatigue in people with I-RMDs and to summarise their safety in…
Abstract Number: 0013 • ACR Convergence 2023
A Proliferating T Cell Signature in Blood Is Associated with Response to JAK Inhibitor Therapy in Rheumatoid Arthritis Patients
Mehreen Elahee¹, Kathryne Marks², Ifeoluwakiisi Adejoorin², Lin Chen², Derrick Todd², Jonathan Coblyn², Elena Massarotti², Susan Ritter², Michael Weinblatt³, Daniel Solomon⁴ and Deepak Rao², ¹University of Pittsburgh Medical Center, Pittsburgh, PA, ²Brigham and Women's Hospital, Boston, MA, ³Harvard Medical School, Waban, MA, ⁴Brigham and Women's Hospital, Newton, MA
Background/Purpose: There are multiple DMARDs available to treat rheumatoid arthritis (RA) yet there are no widely used predictive biomarkers to guide selection of a specific…
Abstract Number: 2580 • ACR Convergence 2023
High-intensity Resistance Training Improves Quality of Life, Muscle Endurance and Strength in Patients with Myositis
Kasper Jensen¹, Per Aagaard², Charlotte Suetta³, Jakob Nielsen², Rune Bech⁴, Henrik Schrøder¹, Casper Simonsen¹, Jan Christensen¹ and Louise Pyndt Diederichsen⁵, ¹University Hospital of Copenhagen, Rigshospitalet, Copenhagen, Denmark, ²University of Southern Denmark, Odense, Denmark, ³Bispebjerg Hospital, Copenhagen, Denmark, ⁴Zealand University Hospital, Koege, Dragør, Denmark, ⁵University Hospital of Copenhagen, Rigshospitalet, Dragør, Denmark
Background/Purpose: Myositis is associated with muscle impairment, which impacts quality of life. The purpose of this study was to investigate the effects of high-intensity strength…
Abstract Number: 0317 • ACR Convergence 2023
Long-term Effectiveness of a Lifestyle Program for Osteoarthritis: One-year Follow-up of the “Plants for Joints” Randomized Clinical Trial
Carlijn Wagenaar¹, Wendy Walrabenstein¹, Marike Van der Leeden², Martijn Gerritsen², Jos W.R. Twisk¹, Martin van der Esch², Henriët van Middendorp³, Peter Weijs⁴ and Dirkjan van Schaardenburg⁵, ¹Amsterdam University Medical Centers, Amsterdam, Netherlands, ²Reade Rheumatology Center, Amsterdam, Netherlands, ³Leiden University, Leiden, Netherlands, ⁴Amsterdam University of Applied Sciences, Amsterdam, Netherlands, ⁵Reade, Amsterdam, Netherlands
Background/Purpose: The 16-week Plants for Joints (PFJ) multidisciplinary lifestyle program, based on a whole-food plant-based diet, physical activity, and stress management, significantly reduced The Western…
Abstract Number: 2596 • ACR Convergence 2023
Head-To-Head Comparison of the Effectiveness of Tocilizumab, Rituximab, Mycophenolate Mofetil, and Cyclophosphamide in Patients with SSc-ILD from the EUSTAR Database
Qingran Yan¹, Cosimo Bruni², Alexandru Garaiman², Carina Mihai², Suzana Jordan², Mike Becker³, Muriel Elhai⁴, Rucsandra Dobrota², liubov Petelytska³, Anna-Maria Hoffmann-Vold⁵, Joerg Henes⁶, Eric Hachulla⁷, Elise Siegert⁸, Alexandra Balbir-Gurman⁹, Giovanna Cuomo¹⁰, Gabriela Riemekasten¹¹, Stefan Heitmann¹², valeria Riccieri¹³, Susanne Ullman¹⁴, Petros Sfikakis¹⁵, Francesca Ingegnoli¹⁶, Vera Bernardino¹⁷, Marie-Elise Truchetet¹⁸, Francesco Del Galdo¹⁹, SHUANG YE²⁰ and Oliver Distler², ¹Department of Rheumatology, University Hospital Zurich, Zurich, Swaziland, ²Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ³Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, ⁴University Hospital zurich, University of Zurich, Zurich, Switzerland, ⁵Oslo University Hospital, Oslo, Norway, ⁶University Hospital Tuebingen, Tuebingen, Germany, ⁷University of Lille, Lille, France, ⁸Department of Rheumatology, Charité University Hospital, Charité Platz 1, D-10117, Berlin, Germany, ⁹Rheumatology Institute, Rambam Health Care Campus and Rappaport Faculty of |Medicine, Technion, Haifa, Israel, ¹⁰Department of Precision Medicine, “Luigi Vanvitelli” University of Campania, Naples, Italy, ¹¹University Clinic Schleswit-Holstein (UKSH), Lübeck, Germany, ¹²Department of Rheumatology, Marienhospital Stuttgart, Böheimstrasse 37, D-70199, Stuttgart, Germany, ¹³Department of Clinical, Internal and Cardiovascular Specialities, Sapienza University of Rome, Roma, Italy, ¹⁴Department of Dermatology, University Hospital of Copenhagen, Hospital Bispebjerg, Copenhagen, Denmark, ¹⁵National Kapodistrian University of Athens Medical School, Athens, Greece, ¹⁶Universita' degli Studi di Milano, Milano, Italy, ¹⁷Centro Hospitalar Lisboa Central, Lisbon, Portugal, ¹⁸Bordeaux University Hospital, Bordeaux, France, ¹⁹University of Leeds - Leeds Institute of Rheumatic and Muskuloskeletal Medicine, Leeds, United Kingdom, ²⁰Department of Rheumatology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
Background/Purpose: Tocilizumab (TCZ), rituximab (RTX), mycophenolate mofetil (MMF), and cyclophosphamide (CYC) are the immunosuppressants (IS) with the current best evidence for the treatment of systemic…
Abstract Number: 0328 • ACR Convergence 2023
From Patient Needs to Platform Design: Using Patient Preference to Guide the Development of a Post-Viral Fibromyalgia Management App
Marc Blanchard¹, Pedro Ming Azevedo², Tiffany Prétat², Cinja Koller² and Thomas Hügle³, ¹Dept. of Rheumatology, University Hospital Lausanne (CHUV) and University Lausanne, Lausanne, Switzerland, ²Lausanne University Hospital, Lausanne, Switzerland, ³Dept. of Rheumatology, University Hospital Lausanne (CHUV) and University of Lausanne, Lausanne, Switzerland
Background/Purpose: Post-viral fibromyalgia is a chronic condition that can develop in individuals following a viral infection, such as COVID-19. Recent studies have shown that approximately…
Abstract Number: 2597 • ACR Convergence 2023
Fecal Microbiota Transplantation in Patients with Systemic Sclerosis and Lower Gastrointestinal Tract Symptoms: Data from the ReSScue Phase 2 Randomized Clinical Trial
Anna-Maria Hoffmann-Vold¹, Havard Fretheim¹, Imon Barua¹, Maylen Nordgård Carstens¹, Henriette Didriksen², Vikas Sarna¹, Knut AE Lundin¹, Oliver Distler³, Dinesh Khanna⁴, Elizabeth Volkmann⁵, Oyvind Midtvedt¹, Tore Midtvedt⁶, Alvilde Dhainaut⁷, Anne-Kristine H Halse⁸, Gunnstein Bakland⁹, Inge Olsen¹, Maiju E Pesonen¹ and Oyvind Molberg¹⁰, ¹Oslo University Hospital, Oslo, Norway, ²Oslo University Hospital, Moss, Norway, ³Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ⁴University of Michigan, Ann Arbor, MI, ⁵University of California Los Angeles, Los Angeles, CA, ⁶Karolinska Institutet, Stockholm, Sweden, ⁷St. Olav, Trondheim, Norway, ⁸University Hospital Bergen, Bergen, Norway, ⁹University Hospital of North Norway, Tromsø, Norway, ¹⁰Dept of Rheumatology, University Hospital Oslo, Oslo, Norway
Background/Purpose: Lower gastrointestinal tract (GIT) complications are common in patients with systemic sclerosis (SSc), associate with a high disease burden, and current treatment alternatives are…
Abstract Number: 0470 • ACR Convergence 2023
Educational Intervention to Increase Contraception Screening and Documentation for Reproductive-Aged Women Seen in an Academic Rheumatology Clinic
Caroline Siegel¹, Deanna Jannat-Khah¹, Avi Mikhaylov¹, Erika Abramson², Nancy Pan¹ and Lisa Sammaritano³, ¹Hospital for Special Surgery, New York, NY, ²Weill Cornell Medicine, New York, NY, ³Hospital for Special Surgery, Weill Cornell Medicine, New York, NY
Background/Purpose: Only one-third of reproductive-aged women with rheumatic disease (RD) are prescribed effective contraception, even if prescribed teratogenic medications (Talabi et al. Arthritis Care Res.…
Abstract Number: PP01 • ACR Convergence 2023
You Can’t Get This from a Doctor: The Role of Support Groups for Adults Aged 25-55 Living with Arthritis
Eileen Davidson, Global Healthy Living Foundation, Burnaby, BC, Canada
Background/Purpose: Living with a rheumatic condition comes with unique concerns specific to mental and social health like struggling with fatigue, anxiety, depression, and isolation, all…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].